Stock GSK GSK PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E.
Other stock markets
 11:35:15 2024-04-26 am EDT 		5-day change 1st Jan Change
1,653 GBX +0.76% Intraday chart for GSK plc +3.38% +13.98%
Apr. 25 Sector Update: Health Care Stocks Drop in Afternoon Trading MT
Apr. 25 GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 88,051 66,801 80,458 58,381 59,112 67,543 - -
Enterprise Value (EV) 1 113,773 87,581 100,296 75,578 74,152 79,709 76,474 71,563
P/E ratio 19.2 x 11.8 x 18.6 x 3.93 x 11.9 x 11.9 x 10.6 x 9.5 x
Yield 4.5% 5.96% 4.98% 4.26% 4% 3.68% 3.92% 4.19%
Capitalization / Revenue 2.61 x 1.96 x 2.36 x 1.99 x 1.95 x 2.15 x 2.02 x 1.92 x
EV / Revenue 3.37 x 2.57 x 2.94 x 2.58 x 2.45 x 2.53 x 2.29 x 2.03 x
EV / EBITDA 9.51 x 9.19 x 8.85 x 7.23 x 6.37 x 7.5 x 6.57 x 5.62 x
EV / FCF 22.4 x 16.2 x 22.6 x 12.1 x 13.6 x 12 x 10.6 x 9.34 x
FCF Yield 4.46% 6.17% 4.42% 8.28% 7.36% 8.36% 9.4% 10.7%
Price to Book 7.35 x 4.58 x 5.34 x 5.47 x 4.4 x 4.08 x 3.38 x 2.82 x
Nbr of stocks (in thousands) 3,959,572 3,982,185 4,006,383 4,060,999 4,076,145 4,086,063 - -
Reference price 2 22.24 16.78 20.08 14.38 14.50 16.53 16.53 16.53
Announcement Date 2/5/20 2/3/21 2/9/22 2/1/23 1/31/24 - - -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 33,754 34,099 34,114 29,324 30,328 31,478 33,379 35,240
EBITDA 1 11,968 9,530 11,330 10,449 11,635 10,621 11,639 12,742
EBIT 1 8,972 8,906 8,806 8,151 8,786 9,087 10,090 11,191
Operating Margin 26.58% 26.12% 25.81% 27.8% 28.97% 28.87% 30.23% 31.76%
Earnings before Tax (EBT) 1 6,221 6,968 5,442 5,628 6,064 7,612 8,591 9,525
Net income 1 4,645 5,749 4,385 14,956 4,928 5,664 6,397 7,107
Net margin 13.76% 16.86% 12.85% 51% 16.25% 17.99% 19.16% 20.17%
EPS 2 1.158 1.426 1.082 3.662 1.216 1.386 1.560 1.740
Free Cash Flow 1 5,073 5,406 4,437 6,260 5,454 6,661 7,187 7,658
FCF margin 15.03% 15.85% 13.01% 21.35% 17.98% 21.16% 21.53% 21.73%
FCF Conversion (EBITDA) 42.39% 56.73% 39.16% 59.91% 46.88% 62.71% 61.75% 60.1%
FCF Conversion (Net income) 109.21% 94.03% 101.19% 41.86% 110.67% 117.6% 112.35% 107.75%
Dividend per Share 2 1.000 1.000 1.000 0.6125 0.5800 0.6082 0.6488 0.6918
Announcement Date 2/5/20 2/3/21 2/9/22 2/1/23 1/31/24 - - -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 9,077 9,527 9,780 6,929 7,829 7,376 6,951 7,178 8,147 8,052 7,060 7,557 8,551 8,227 7,590
EBITDA 1 3,860 2,406 3,317 2,639 3,561 1,602 2,732 2,622 3,351 2,930 2,406 2,591 3,071 2,056 -
EBIT 1 2,874 1,893 2,613 2,008 2,605 1,595 2,092 2,170 2,772 1,752 2,099 2,211 2,807 1,850 2,408
Operating Margin 31.66% 19.87% 26.72% 28.98% 33.27% 21.62% 30.1% 30.23% 34.02% 21.76% 29.74% 29.26% 32.82% 22.49% 31.73%
Earnings before Tax (EBT) 1 1,748 706 2,598 896 1,012 1,626 1,907 1,987 1,791 379 1,696 1,825 2,487 1,506 -
Net income 1 1,168 749 1,802 975 10,315 1,495 1,490 1,624 1,464 350 1,297 1,419 1,859 1,183 -
Net margin 12.87% 7.86% 18.43% 14.07% 131.75% 20.27% 21.44% 22.62% 17.97% 4.35% 18.37% 18.77% 21.74% 14.38% -
EPS 2 0.2888 0.1838 0.4488 0.2080 2.523 0.3650 0.3650 0.4010 0.3610 0.0860 0.3142 0.3430 0.4494 0.2851 -
Dividend per Share 2 0.2375 0.2875 0.1750 0.1625 0.1375 0.1375 0.1400 0.1400 0.1400 0.1600 0.1475 0.1475 0.1475 0.1575 0.1576
Announcement Date 10/27/21 2/9/22 4/27/22 7/27/22 11/2/22 2/1/23 4/26/23 7/26/23 11/1/23 1/31/24 - - - - -
1GBP in Million2GBP
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 25,722 20,780 19,838 17,197 15,040 12,167 8,932 4,021
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.149 x 2.18 x 1.751 x 1.646 x 1.293 x 1.146 x 0.7674 x 0.3155 x
Free Cash Flow 1 5,073 5,406 4,437 6,260 5,454 6,661 7,187 7,658
ROE (net income / shareholders' equity) 75% 44.4% 38.2% 43.9% 52.5% 40.3% 36.7% 33.9%
ROA (Net income/ Total Assets) 8.9% 7.18% 5.5% 8.08% 10.5% 9.57% 10.4% 11%
Assets 1 52,185 80,062 79,768 185,120 46,727 59,185 61,745 64,857
Book Value Per Share 2 3.020 3.660 3.760 2.630 3.290 4.050 4.890 5.860
Cash Flow per Share 2 2.000 2.090 1.960 1.810 1.670 1.760 1.850 1.950
Capex 1 1,265 1,226 1,172 1,143 1,314 1,366 1,436 1,492
Capex / Sales 3.75% 3.6% 3.44% 3.9% 4.33% 4.34% 4.3% 4.23%
Announcement Date 2/5/20 2/3/21 2/9/22 2/1/23 1/31/24 - - -
1GBP in Million2GBP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for GSK plc

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
16.53 GBP
Average target price
20.06 GBP
Spread / Average Target
+21.34%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
GSK PLC Stock GSK plc
+13.98% 84.13B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. GSK Stock
  4. Financials GSK plc